We've moved! Same resources, new address:

Find resources

Total results with these characteristics: 201

Disease: Meningococcus

Page 8 of 11
Phenotypic and Genotypic Characterization of Meningococcal Carriage and Disease Isolates in Burkina Faso After Mass Vaccination With a Serogroup A Conjugate Vaccine

The conjugate vaccine against serogroup A Neisseria meningitidis, MenAfriVac, was first introduced in mass vaccination campaigns of the 1- to 29-year-olds in Burkina Faso in 2010. This study, published in BMC Infectious Diseases, genetically …

Author: Kristiansen PA, Ba AK, Sanou I, et al.

Publication date: 2013

The Pink Book—Epidemiology and Prevention of Vaccine-Preventable Diseases

This book provides physicians, nurses, nurse practitioners, physician assistants, pharmacists, and others with the most comprehensive information on vaccine-preventable diseases. In addition to chapters on more general vaccine-related topics, it …

Author: US Centers for Disease Control and Prevention

Publication date: 2015

Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines

Invasive meningococcal disease (IMD) is a serious public health threat, characterized by rapid symptom onset and high fatality rate, even after treatment. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for …

Author: Poland GA

Publication date: 2010

Prevention of Secondary Cases of Meningococcal Disease in Household Contacts by Vaccination

This article, published in The British Medical Journal, describes a study of secondary meningococcal disease infection in which researchers used either meningococcal or tetanus toxoid vaccine to immunize household contacts of patients with …

Author: Greenwood BM, Hassan-King M, Whittle HC

Publication date: 1978

Priorities for Research on Meningococcal Disease and the Impact of Serogroup A Vaccination in the African Meningitis Belt

To review how the research agenda for meningococcal disease in Africa has been changed by the advent of a serogroup A polysaccharide/tetanus toxoid protein conjugate vaccine and to define a new set of research priorities for study of meningococcal …

Author: Greenwood B

Publication date: 2013

Product Development Partnerships Hit Their Stride: Lessons from Developing a Meningitis Vaccine for Africa

This article, published in Health Affairs, provides an overview of the Meningitis Vaccine Project as an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. The Meningitis Vaccine …

Author: Bishai DM, Champion C, Steele ME, Thompson L

Publication date: 2011

The Promise of Conjugate Vaccines for Africa

This article, published in Vaccine, emphasizes the importance of capsular polysaccharide vaccines for preventing disease caused by Neisseria meningitidis and Streptococcus pneumoniae in Africa, reiterating that these vaccines have been proven safe …

Author: Kieny MP, LaForce FM

Publication date: 2007

Prospective Cohort Study of Disabling Sequelae and Quality of Life in Children With Bacterial Meningitis in Urban Senegal

This article, published in the Pediatric Infectious Disease Journal, describes a study to investigate disabling sequelae among a cohort of children diagnosed with bacterial meningitis in urban Dakar, Senegal. Data from the study suggest that …

Author: Edmond K, Dieye Y, Griffiths UK, et al.

Publication date: 2010

Prospects for Vaccine Prevention of Meningococcal Infection

This article, published in Clinical Microbiology Reviews, reviews the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the polysaccharide conjugate …

Author: Harrison LH

Publication date: 2006

Protecting Aluminum-Adjuvanted Vaccines From Freeze Damage

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global health …

Author: PATH

Publication date: 2012

Protecting the Herd: The Remarkable Effectiveness of the Bacterial Meningitis Polysaccharide-Protein Conjugate Vaccines in Altering Transmission Dynamics

The polysaccharide-protein conjugate vaccines against the pathogens responsible for bacterial meningitis have demonstrated remarkable effectiveness, far beyond the predicted individual efficacy. Approximately half of the effectiveness of these …

Author: Stephens DS

Publication date: 2011

Protection From Routine Vaccination at the Age of 14 Months With Meningococcal Serogroup C Conjugate Vaccine in the Netherlands

This article, published in The Pediatric Infectious Disease Journal, reviews routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign, which has reduced the incidence of meningococcal C …

Author: de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A

Publication date: 2006

Protein Carriers of Conjugate Vaccines: Characteristics, Development and Clinical trials

This article, published in Human Vaccines & Immunotherapeutics, discusses the conjugate vaccines for preventing infections caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis. It specifically …

Author: Pichichero ME

Publication date: 2013

PubMed Searches: Meningococcus

These pre-formatted PubMed searches will retrieve journal citations and available abstracts that address relevant issues related to meningococcus. Documents may be ordered through Loansome Doc if you have established an agreement with a …

Author: Various

Putting an End to Epidemic Meningitis in Africa

This fact sheet describes PATH’s efforts to eliminate meningococcal meningitis epidemics from Africa. It covers work across meningitis projects, including the development and distribution of MenAfriVac®, the vaccine that has virtually eliminated …

Author: PATH

Publication date: 2017

Recent Developments in Neisseria Meningitidis Group A Conjugate Vaccines

This article, published in Expert Opinion on Biological Therapy, focuses on the development of meningococcal conjugate vaccines for serogroup A, with special emphasis on the needs of Africa. The author discusses the currently available conjugate …

Author: Frasch CE

Publication date: 2005

Report of the Informal Consultation on Meningococcal Carriage Studies in Africa

This report summarizes a meeting organized by the World Health Organization to discuss meningococcal carriage studies in Africa that could provide data to support the introduction of the meningococcal A conjugate vaccine in the region. The …

Author: World Health Organization

Publication date: 2005

Resources: From pneumoACTION to Now

This web page offers a vast array of links to resources on a leading cause of child morbidity and mortality, pneumococcal diseases. It provides information on available vaccines, vaccine safety, disease burden, immunization financing, and other …

Author: International Vaccine Access Center

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis

This article, published in Advances in Therapy, reviews the impacts of 7-valent pneumococcal polysaccharide conjugate vaccine (PCV7) on pneumococcal meningitis. The authors conclude that the results show PCV7 to have significant impact on …

Author: Tin Tin Htar M, Madhava H, Balmer P, Christopoulou D, Menegas D, Bonnet E

Publication date: 2013

A Review of Vaccine Research and Development: Meningococcal Disease

This article, published in the journal Vaccine, reviews the status of research and development of vaccines against meningococcal disease due to Neisseria meningitidis as of 2006. The paper discusses the widespread vaccination with Group C conjugate …

Author: Girard MP, Preziosi MP, Aguado MT, Kieny MP

Publication date: 2006

Page 8 of 11